艾昆纬-印度制药业务季度洞察-2024年第三季度 Indian Pharmaceutical Business Quarterly.docx

IndianPharmaceutical

BusinessQuarterly

Insights-Q32024(Jul-Sep)

ReportReleaseDate:Nov2024

Dataset:TSASep2024

?2024.Allrightsreserved.IQVIA?isaregisteredtrademarkofIQVIAInc.intheUnitedStates,theEuropeanUnion,andvariousothercountries.

Disclaimer

IQVIAisnotan“authorisedperson”forthepurposesoftheFinancialServicesandMarketsAct2000(“FSMA”)anddoesnotprovideinvestmentadviceorcarryonanyotherregulatedactivityunderPartIIoftheFSMA2000(RegulatedActivities)Order2001

Theforecasts,projections,andrelatedinformationcontainedhereinaremadeandprovidedsubjecttotheassumptions,methodologies,caveats,andvariablesdescribedinthisreportandarebasedonthirdpartysourcesanddatareasonablybelievedtobereliable.No

warrantyismadeastothecompletenessoraccuracyofsuchthirdpartysourcesordata

Thisreport,inpartorinwhole,isnotintendedtoconstituteinvestmentadvice,andisnotarecommendationtopurchaseornotpurchase,anendorsementof,oranopinionastothevalueof,anysecurityoranyinvestmentinstrumentofanyentity

Aswithanyattempttoestimatefutureevents,theforecasts,projections,conclusions,andotherinformationincludedhereinaresubjecttocertainrisksanduncertainties,andarenottobeconsideredguaranteesofanyparticularoutcome

Thisreportshallnotbepublished,norshallanypublicreferencestoIQVIAbemaderegardingtheseservicesorthisreport,withoutIQVIA’priorwrittenapproval.Whensoprovided,thisreportandtheinformationhereinmustalwaysbeprovidedandusedinitsentirety,includingthiscompleteDisclaimerpage

ThisreportissubjecttotheIQVIAGeneralTermsandConditions.

IQVIA1

IndiapharmaperformedwellinH12023H12024intermsofvaluecompared

toH12022,Unitsdegrowthprimarilyduetoslowdowninacutetherapies

H1

H1Highlights(Apr’24-Sept’24),ValinCr.

116,732

107,666

107,666

99,505

9,0